Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
SAN FRANCISCO, Aug. 8, 2013 /PRNewswire via COMTEX/ -- Nektar Therapeutics /quotes/zigman/89920/quotes/nls/nktr NKTR -1.35% today reported its financial results for the second quarter ended June 30, 2013.
Cash and investments in marketable securities at June 30, 2013 were $226.9 million.
“I am very pleased with Nektar’s performance this year,” said Howard W. Robin, President and Chief Executive Officer of Nektar. “AstraZeneca has confirmed that they will be filing both the naloxegol NDA and MAA in September. Naloxegol could be the first once-daily oral medication to treat patients with opioid-induced constipation.
Hey, check out all the engineering jobs. Post your resume today!
